About Deep Genomics
Deep Genomics uses AI to discover and develop genetic medicines, identifying disease-causing genetic variants and designing therapies to correct them.
Mission & Story
Mission
Building, running and improving the world's best Biological Foundation Models in an effort to transform the field of drug discovery - finding molecules and targets others would miss, and accelerating their development into life changing medicines for patients
Founding Story
Founded in 2015 by Brendan Frey, Ph.D., an internationally acclaimed entrepreneur, engineer and scientist who made fundamental contributions in deep learning and genomic medicine. His pioneering work on AI systems that could accurately predict normal and pathological cell and genome biology led to the first AI system for predicting pathogenic mutations and identifying therapeutic targets.
Clinical Focus
Medical conditions and clinical areas addressed by Deep Genomics.
Who It Serves
Milestones & Awards
Recent Milestones
REPRESS model announced May 2025; Executive hires including Monika Kowalczyk MD PhD as VP Platform Technology and Greg Hoffman PhD as CSO in April 2025; Thong Q. Le and Paul Sekhri joined Board of Directors October 2025; Cambridge MA office expansion June 2024; BigRNA foundation model launched 2021 with significant enhancements through 2025
Awards & Recognition
Gold Stevie Award 2025 for Technology Excellence (CEO Brian O'Callaghan as Biotech Executive of the Year); Stevies 2024 BioTechnology Company of the Year
Key Partnerships
Social & Media
Follow on
Latest Updates
From skeptic to builder: why I changed my mind about AI for biology
9mo ago
The TechBio way: Brendan Frey talks genomics, AI, and RNA
11mo ago
Why AI for drug discovery will far exceed current expectations
1y ago
Deep Genomics Expands AI Foundation Model Platform for Decoding RNA Biology
1y ago
RNA Foundation Models to Improve Pharma R&D Productivity
1y ago
Company Details
- Founded
- 2015
- Headquarters
- Toronto, Canada
- Employees
- 125
- Stage
- series c
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.